Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.39 |
| ▸ | AR | P10275 | 2/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6939294 | 0.92 | PPARG (0.41) | PPARDPPARGMRGPRX4PTGER1AR | |
| SCHEMBL6939517 | 0.89 | PPARG (0.38) | PPARDPPARGMRGPRX4PTGER1AR | |
| SCHEMBL7561553 | 0.77 | PPARD (0.38) | PPARDPPARGMRGPRX4PTGER1EPHX2 | |
| SCHEMBL7187595 | 0.74 | CRHR1 (0.41) | AR | |
| SCHEMBL6554549 | 0.73 | SLC6A9 (0.46) | PPARDPPARGMRGPRX4PTGER1SLC6A9 | |
| SCHEMBL6554509 | 0.73 | EPHX2 (0.46) | PPARDPPARGMRGPRX4EPHX2 | |
| Hydrochloric Acid SCHEMBL6554810 | 0.73 | SLC6A9 (0.45) | PPARDPPARGMRGPRX4PTGER1SLC6A9 | |
| SCHEMBL5103863 | 0.72 | TTR (0.43) | AR | |
| SCHEMBL6936342 | 0.71 | GABRA1 (0.38) | MRGPRX4PTGER1 | |
| SCHEMBL6555857 | 0.71 | SLC6A9 (0.43) | PPARDPPARGMRGPRX4PTGER1PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370540-A1 | ANTI-THROMBOTIC CARBOXYLIC ACID AMIDES, THE PRODUCTION THEREOF AND USE OF THE SAME AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-12-17 | — | — | EP | disclosed |
| US-20020183519-A1 | Antithrombotic carboxylic acid amides | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-12-05 | — | — | US | disclosed |
| WO-2002072558-A1 | ANTI-THROMBOTIC CARBOXYLIC ACID AMIDES, THE PRODUCTION THEREOF AND USE OF THE SAME AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183519-A1 | Antithrombotic carboxylic acid amides | SERPINC1, TFPI, F2 | PPARD 637/4885PPARG 493/4885MRGPRX4 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.